Brian Rini, MD, FASCO
Brian I. Rini, MD, FASCO, is Ingram Professor of Medicine and Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and co-host of The Uromigos podcast.
Articles by Brian Rini, MD, FASCO
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
The panel discussed important takeaways from RCC studies presented at ASCO GU.
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Dr. McDermott advocates for immune therapy in frontline RCC care.
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.